CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...
Phase 3
Seattle, Washington, United States of America and 164 other locations
Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children ...
Phase 1
Seattle, Washington, United States of America and 23 other locations
allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid...
Phase 3
Seattle, Washington, United States of America and 23 other locations
PK of APG-2575 in combination with Azacitidine in the patients with AML/MPAL or MDS/CMML. The study consists of dose escalation (Part I) and...
Phase 1, Phase 2
Seattle, Washington, United States and 8 other locations
Study ASTX030-01 is designed to move efficiently from Phase 1 to Phase 3. Phase 1 consists of an open-label Dose Escalation Stage (Stage A) using mul...
Phase 2, Phase 3
Seattle, Washington, United States and 20 other locations
or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or i...
Phase 1, Phase 2
Seattle, Washington, United States and 26 other locations
when co administered with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute...
Phase 3
Seattle, Washington, United States and 108 other locations
\[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse w...
Phase 3
Seattle, Washington, United States and 78 other locations
in combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who ar...
Phase 1, Phase 2
Seattle, Washington, United States and 33 other locations
This is a Phase 1/2a, multicenter, open-label, first-in-human (FIH) study of VOR33 in participants with AML or MDS who are undergoing human ...
Phase 1, Phase 2
Seattle, Washington, United States of America and 14 other locations
Clinical trials
Research sites
Resources
Legal